FDA approved atezolizumab for adjuvant treatment following resection and platinum-based chemotherapy in patients with stage 2 to 3A non-small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells.

[…] a mutation in the EGFR gene or the ALK gene. In adults whose cancer has gotten worse during or after treatment with platinum chemotherapy. For patients whose cancer has a mutation in the EGFR gene or ALK gene, atezolizumab is used if their disease has gotten worse after treatment with FDA-approved therapy for these mutations.

Adding atezolizumab and tiragolumab to chemotherapy may improve survival in extensive stage small cell lung cancer, with further research needed.

Recent advancements have led to the incorporation of immunotherapy and targeted therapy into combination treatment plans: Immunotherapy: Drugs like pembrolizumab and atezolizumab are now used in combination with chemotherapy as first-line treatments for certain types of non-small cell lung cancer (NSCLC). Targeted Therapy: For patients with specific genetic mutations, targeted therapies like osimertinib or […]

[…] Patients with NSCLC and SBM age 65 years or older at diagnosis from 2010 to 2019 SEER-Medicare database and received US Food and Drug Administration–approved ICIs (pembrolizumab/nivolumab/ipilimumab/ atezolizumab/durvalumab/cemiplimab) and/or chemotherapy (platinum-based doublets/taxane/pemetrexed/gemcitabine) as first-line systemic treatment were included, excluding those with no cranial radiation or ever being treated with targeted therapies. Overall survival time […]

[…] the first-line treatment for extensive-stage small cell lung cancer. Immunotherapies can prolong the body’s response to conventional chemotherapy and offers a promising addition to SCLC treatment. The immunotherapy drugs atezolizumab and durvalumab block the protein PD-L1 and boost the body’s immune response to cancer cells. When used in combination with chemotherapy, these drugs increased overall survival […]

[…] patients with ES-SCLC. Combined, these studies randomly assigned 245 patients to receive either an IV infusion of trilaciclib or a placebo before chemotherapy regimens containing carboplatin/etoposide (+/- atezolizumab) and topotecan. Approximately 90% of all patients with ES-SCLC will receive at least one of these regimens during the course of their treatment. The studies compared […]